<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627848</url>
  </required_header>
  <id_info>
    <org_study_id>KUH5772749</org_study_id>
    <nct_id>NCT00627848</nct_id>
  </id_info>
  <brief_title>Rivastigmine in Mild Alzheimer's Disease, FMRI Study</brief_title>
  <acronym>ADFRMI</acronym>
  <official_title>Effect of Rivastigmine on FMRI in Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effect of rivastigmine given as an acute dose
      compared to placebo and after 1 month chronic dosing on fMRI response during a face
      recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated
      with long term treatment effect at 6 months and 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FMRI response in face recognition task</measure>
    <time_frame>at baseline and at 1 mo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment response measured by ADAS-cog</measure>
    <time_frame>at 6 month and 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Alzheimer' Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivastigmine</intervention_name>
    <description>Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Probable Alzheimer's disease according to the NINCDS-ADRDA criteria

          -  mild disease, CDR 1

          -  the clinician is planning to start anticholinesterase treatment

        Exclusion Criteria:

          -  cognitive impairment for other reason than Alzheimer's disease

          -  severe depression

          -  other unstable physical disease

          -  medal in body prevention MRI examination, claustrophobia

          -  cardiac pacemaker

          -  other significant neurologic or psychiatric disease

          -  contraindication for anticholinesterase treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilkka Soininen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kuopio University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2008</study_first_posted>
  <last_update_submitted>October 27, 2011</last_update_submitted>
  <last_update_submitted_qc>October 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kuopio University Hospital</investigator_affiliation>
    <investigator_full_name>Hilkka Soininen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>fmri</keyword>
  <keyword>face recognition</keyword>
  <keyword>rivastigmine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

